Event-Driven Stocks

AYTU BIOPHARMA, INC

AYTUNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 3 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$66.4M$65.2M$107.4M$96.7M$65.6M$27.6M
Operating income−$7.8M−$1.6M−$17.1M−$109.9M−$58.9M−$21.1M
Net income−$13.6M−$15.8M−$17.1M−$108.8M−$58.3M−$13.6M
Total assets$124.2M$118.1M$136.5M$137.6M$265.7M$152.8M
Total liabilities——$97.1M$93.3M$128.1M$57.8M
Equity$19.0M$27.7M$39.4M$44.3M$137.6M$95.0M
EPS (diluted)$-2.16$-2.86$-5.11$-74.01$-3.48—
Shares out.9.9M6.1M5.5M62.4M27.6M125.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−11.8%
Net margin
−20.4%
Return on equity
−71.5%
Return on assets
−10.9%
Return on capital (ROCE)
−12.8%
Liabilities / assets
—
Debt / equity
—
Book value / share
$1.91
Revenue growth (YoY)
1.8%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−9.4%clean
Piotroski F-Score
3/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
73
/ 100
Profitability 0Growth 100Catalyst 100Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 3 warning● 2 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

FDA-approved drugs

openFDA · most recent
  • METADATE CDApr 3, 2001

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
11 acquisitions0 disposals2 open-market buy(s)net +203,336 shares · last 11
InsiderDateTypeSharesPrice
Pyszczymuka GregOfficer — Chief Commercial OfficerOct 3, 2025Grant12,500$0.00
Disbrow JarrettOfficer — Chief Business OfficerOct 3, 2025Grant19,606$0.00
Selhorn Ryan JOfficer — Chief Financial OfficerOct 3, 2025Grant16,243$0.00
Disbrow Joshua R.Officer — Chief Executive OfficerOct 3, 2025Grant31,446$0.00
Liu Vivian HDirectorOct 3, 2025Grant10,000$0.00
Jain AbhinavDirectorOct 3, 2025Grant10,000$0.00
Dockery CarlDirectorOct 3, 2025Grant10,000$0.00
Donofrio John Jr.DirectorOct 3, 2025Grant10,000$0.00
Disbrow JarrettOfficer — Chief Business OfficerJun 9, 2025Buy16,666$1.50
Disbrow Joshua R.Officer — Chief Executive OfficerJun 9, 2025Buy66,666$1.50
Pyszczymuka GregOfficer — Chief Commercial OfficerMar 31, 2025Option exercise209—

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026457,7917.1-9.4%
Apr 30, 2026505,36819.7+0.6%
Apr 15, 2026502,21213.6-0.2%
Mar 31, 2026503,3619.9-0.9%
Mar 13, 2026507,87911.7+7.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)